DTIL – Precision BioSciences, Inc.
Precision BioSciences, Inc.DTIL
$4.95Name : Precision BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $52,222,992.00
EPSttm : 1.04
Precision BioSciences, Inc.
$4.95
3.79%$0.195Float Short %
22.45
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.65
EPS Last/This Y
-11.27
EPS This/Next Y
1.34
Price
4.97
Target Price
30.5
Analyst Recom
1
Performance Q
-2.37
Relative Volume
0.58
Beta
1.51
Ticker: DTIL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | DTIL | 4.47 | N/A | N/A | 0 |
| 2025-04-15 | DTIL | 5.52 | N/A | N/A | 0 |
| 2025-04-16 | DTIL | 5.01 | N/A | N/A | 0 |
| 2025-04-17 | DTIL | 4.95 | N/A | N/A | 0 |
| 2025-04-18 | DTIL | 5.02 | N/A | N/A | 0 |
| 2025-04-21 | DTIL | 5.16 | N/A | N/A | 0 |
| 2025-04-22 | DTIL | 5.32 | N/A | N/A | 0 |
| 2025-04-23 | DTIL | 5.69 | N/A | N/A | 0 |
| 2025-04-24 | DTIL | 5.5 | N/A | N/A | 0 |
| 2025-04-25 | DTIL | 5.33 | N/A | N/A | N/A |
| 2025-04-28 | DTIL | 5.11 | N/A | N/A | N/A |
| 2025-04-29 | DTIL | 5.25 | N/A | N/A | 0 |
| 2025-04-30 | DTIL | 5.63 | N/A | N/A | 0 |
| 2025-05-01 | DTIL | 5.72 | N/A | N/A | 0 |
| 2025-05-02 | DTIL | 5.75 | N/A | N/A | 0 |
| 2025-05-05 | DTIL | 5.62 | N/A | N/A | 0 |
| 2025-05-06 | DTIL | 5.1 | N/A | N/A | 0 |
| 2025-05-07 | DTIL | 5.17 | N/A | N/A | 0 |
| 2025-05-08 | DTIL | 5.13 | N/A | N/A | 0 |
| 2025-05-09 | DTIL | 5.19 | N/A | N/A | 0 |
| 2025-05-12 | DTIL | 5.23 | N/A | N/A | 0 |
| 2025-05-13 | DTIL | 5.17 | N/A | N/A | 0 |
| 2025-05-14 | DTIL | 4.96 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | DTIL | 4.46 | - | - | -10.22 |
| 2025-04-15 | DTIL | 5.52 | - | - | -10.22 |
| 2025-04-16 | DTIL | 5.04 | - | - | -10.22 |
| 2025-04-17 | DTIL | 5.02 | - | - | -10.22 |
| 2025-04-18 | DTIL | 5.02 | - | - | -10.22 |
| 2025-04-21 | DTIL | 5.13 | - | - | -10.22 |
| 2025-04-22 | DTIL | 5.32 | - | - | -10.22 |
| 2025-04-23 | DTIL | 5.68 | - | - | -10.22 |
| 2025-04-24 | DTIL | 5.56 | - | - | -10.22 |
| 2025-04-25 | DTIL | 5.33 | - | - | -10.22 |
| 2025-04-28 | DTIL | 5.11 | - | - | -10.22 |
| 2025-04-29 | DTIL | 5.23 | - | - | -10.22 |
| 2025-04-30 | DTIL | 5.64 | - | - | -10.22 |
| 2025-05-01 | DTIL | 5.72 | - | - | -10.22 |
| 2025-05-02 | DTIL | 5.75 | - | - | -10.22 |
| 2025-05-05 | DTIL | 5.61 | - | - | -10.22 |
| 2025-05-06 | DTIL | 5.12 | - | - | -10.22 |
| 2025-05-07 | DTIL | 5.18 | - | - | -10.22 |
| 2025-05-08 | DTIL | 5.13 | - | - | -10.22 |
| 2025-05-09 | DTIL | 5.13 | - | - | -10.22 |
| 2025-05-12 | DTIL | 5.22 | - | - | -10.22 |
| 2025-05-13 | DTIL | 5.14 | - | - | -10.22 |
| 2025-05-14 | DTIL | 4.97 | - | - | -10.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | DTIL | -5.49 | 45.41 | 21.82 |
| 2025-04-15 | DTIL | -5.49 | 45.41 | 21.82 |
| 2025-04-16 | DTIL | -2.20 | 45.41 | 21.82 |
| 2025-04-17 | DTIL | -2.20 | 45.41 | 21.82 |
| 2025-04-18 | DTIL | -2.20 | 45.41 | 25.34 |
| 2025-04-21 | DTIL | -2.20 | 45.87 | 25.34 |
| 2025-04-22 | DTIL | -1.24 | 45.87 | 25.34 |
| 2025-04-23 | DTIL | -1.24 | 45.87 | 25.34 |
| 2025-04-24 | DTIL | -1.24 | 45.87 | 25.34 |
| 2025-04-25 | DTIL | -1.24 | 45.87 | 25.34 |
| 2025-04-28 | DTIL | -1.24 | 45.87 | 21.96 |
| 2025-04-29 | DTIL | -1.24 | 45.87 | 21.96 |
| 2025-04-30 | DTIL | -1.23 | 45.87 | 21.96 |
| 2025-05-01 | DTIL | -1.23 | 45.87 | 21.96 |
| 2025-05-02 | DTIL | -1.23 | 45.87 | 21.96 |
| 2025-05-05 | DTIL | -3.15 | 22.77 | 21.96 |
| 2025-05-06 | DTIL | -2.84 | 22.77 | 21.96 |
| 2025-05-07 | DTIL | -1.11 | 22.77 | 21.96 |
| 2025-05-08 | DTIL | -1.11 | 22.77 | 21.96 |
| 2025-05-09 | DTIL | -1.11 | 22.77 | 21.96 |
| 2025-05-12 | DTIL | -2.84 | 19.90 | 22.45 |
| 2025-05-13 | DTIL | -2.84 | 19.90 | 22.45 |
| 2025-05-14 | DTIL | -1.11 | 19.90 | 22.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.2
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-2.55
Insider Transactions
-1.11
Institutional Transactions
19.9
Beta
1.51
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
58
Growth Score
45
Sentiment Score
7
Actual DrawDown %
99
Max Drawdown 5-Year %
-99.2
Target Price
30.5
P/E
2.61
Forward P/E
PEG
P/S
0.76
P/B
0.72
P/Free Cash Flow
EPS
1.89
Average EPS Est. Cur. Y
-10.22
EPS Next Y. (Est.)
-8.88
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
10.43
Relative Volume
0.58
Return on Equity vs Sector %
-11
Return on Equity vs Industry %
5.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Precision BioSciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 108
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading